10th NAFLD Study Group Meeting 2022 (3rd virtual)
Thursday 12 – Friday 13 May 2022
16:00-19:00 CET (i.e. Italy)
Mitochondria, Biomarkers, and Treatment of NAFLD
Thursday, May 12
- 16:00 Wellcome / Hannele Yki-Järvinen
NASH and the redox state
Chair Catherine Postic
- 16:05 Jennifer Rieusset, Lyon, France - A new role of endoplasmic reticulum-mitochondria calcium coupling in hepatic insulin resistance and steatosis during MAFLD
- 16:25 Panu Luukkonen, Helsinki, Finland - NASH and the intramitochondrial redox state
- 16:50 Mingfeng Xia, Shanghai, China - Altered redox state predicts NASH in Chinese
17:10 Break
New Insights into circulating and imaging Biomarkers
Chair Amalia Gastaldelli
- 17:25 Sami Qadri, Helsinki, Finland - Impact of obesity on biomarker performance in NAFLD
- 17:55 Detlef Schuppan, Mainz, Germany - Multiprotein platforms and biomarkers of NAFLD
- 18:25 Claude B Sirlin, San Diego, CA, USA - Recent advances in MRE in identifying features of NAFLD
- 18:50 End of Day 1
Friday, May 13
Diet and NAFLD
Chair Hannele Yki-Järvinen
- 16:00 Roy Taylor, Newcastle, UK (20+5 min) - Thresholds for metabolic effects of excess liver fat across the BMI range (ReTUNE and DiRECT trials)
- 16:25 Shira Zelber-Sagi, Tel-Aviv, Israel - Lessons from recent dietary intervention trials
- 16:50 Kitt Petersen, Yale, USA - Mechanisms underlying effects of caloric restriction in NAFLD
17:15 Break
Update on pharmacotherapy of NASH
Chair Bart Staels
- 17:30 Sven Francque, Edegem, Belgium - PPAR agonists: successes and failures
- 17:55 Vlad Ratziu Paris, France - Update on therapeutic targets into clinical development
- 18:20 Closing remarks
For further information contact :
← Return